Osteosarcomas
Efficacy of chemotherapy and interval methotrexate in osteosarcoma deemed inadequate
Published in Vaccine Weekly, April 5th, 2006
According to a study from England, "The prognosis for patients with metastatic or axial-skeletal osteosarcoma is poor. A phase I/II study was conducted of intensive chemotherapy with interval methotrexate, to assess the feasibility, response rate and toxicity in this group of patients. Thirteen patients, median age 18 (range: 8-34), with metastatic or axial-skeletal osteosarcoma were treated with ifosfamide 2.5 g/m2, etoposide 150 mg/m2, and doxorubicin 20 mg/m2 on days 1-3, every 21 days, with interval...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-04-05)
More Articles from Vaccine Weekly
- HIV/AIDS Vaccine
HIV vaccine trial participation barriers among disadvantaged minorities determined - Influenza Vaccines
Influenza virus study demonstrates uneven distribution of MHC class II epitopes - SARS Vaccines
SARS coronavirus vaccine has been developed - Smallpox Vaccines
Vaccinia and smallpox viruses were neutralized by monoclonal antibodies - Vaccine Safety
Sudden infant death syndrome case is linked to hexavalent vaccine - Adenovirus Vaccine
Vaccines elicit CD8+T cell immunity under extreme leukopenia - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
